Loading...
XNAS
ALKS
Market cap8.22bUSD
Aug 03, Last price  
49.53USD
1D
-2.08%
1Q
46.76%
Jan 2017
-11.86%
Name

Alkermes Plc

Chart & performance

D1W1MN
XNAS:ALKS chart
P/E
34.38
P/S
5.63
EPS
1.44
Div yield, %
—
Shrs. gr., 5y
1.22%
Rev. gr., 5y
7.28%
Revenues
1.48b
-5.25%
239,965,000240,717,000326,839,000178,281,000186,640,000389,977,000575,548,000575,548,000618,789,000628,335,000745,694,000903,374,0001,094,274,0001,170,947,0001,038,756,0001,173,751,0001,111,795,0001,663,405,0001,557,632,0001,475,899,000
Net income
242m
-34.16%
9,445,000166,979,000130,505,000-39,626,000-45,540,000-113,678,00024,983,00024,983,000-30,061,000-227,163,000-208,444,000-157,945,000-139,311,000-196,620,000-110,861,000-48,169,000-158,267,000355,757,000367,070,000241,664,000
CFO
521m
+18.59%
116,530,00083,727,00042,424,00034,590,000-12,247,000-5,906,000-2,482,000126,551,00011,139,000-40,360,000-63,802,00019,190,00099,281,00072,077,00082,842,000101,715,00021,044,000401,353,000439,124,000520,754,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
URL
https://www.alkermes.com/
IPO date
Jul 16, 1991
Employees
2,280
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT